hepatocellular carcinoma
Conditions
Interventions
Case series:none
Sponsors
Daping Hospital, Army Medical University,
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: All the specimens collected in this study are all primary liver cancer patients, and the patients do not receive the radiotherapy and chemotherapy or any other treatment, pathological results are confirmed after operation.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria are excluded: 1. Acute pelvic inflammatory diseases or acute onset of chronic pelvic inflammatory diseases; 2. Those who have been confirmed by examination to have gynecological malignant tumors, benign tumors (of which the maximum diameter of uterine fibroids is greater than 3 cm, and submucosal fibroids), specific vaginitis (trichomoniasis vaginitis, fungal vaginitis, chlamydia vaginitis, gonococcal vaginitis), acute cervicitis, endometriosis, myometriosis, pelvic venous congestion, tuberculous pelvic inflammatory disease, abnormal uterine bleeding and other diseases caused by related symptoms; 3. Insertion of an IUD in the past 3 months; Absence of uterus and bilateral appendages; 4. Users who take painkillers for a long time or excessive painkillers (take painkillers for more than 10 days within 1 month); 5 Have received relevant treatment or taken drugs with similar functional indications within 1 month before screening; 6. Patients with severe heart, lung, brain and hematopoietic system diseases, malignant tumors; 7. Those with related symptoms caused by anxiety, depression, etc. (depression scale and anxiety scale >= 5 points); 8. Persons with intellectual disabilities or mental illnesses; 9. Suspected or indeed have a history of smoking, alcohol or drug abuse; 10. Positive pregnancy test, pregnant or lactating women, and those with pregnancy plans in the past 4 months; 11. Those who are allergic to the constitution and are known to be allergic to the constituent components of the drug; 12. Screening those who have participated in other clinical trials within 3 months before screening; 13. Researchers who do not believe that they are suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ultrasound/MRI;Pain Visual Analogue Scale (VAS) score;Local sign score;TCM syndrome score; | — |
Secondary
| Measure | Time frame |
|---|---|
| S-36 Health Questionnaire (Medical Outcomes Study Health Survey Short Form-36 Item);Self-rating Depression Scale;self-rating anxiety scale; | — |
Countries
China
Contacts
Public Contactzhoubo
Daping Hospital, Army Medical University,
Outcome results
None listed